Education
About Us
Working with TipRanks
Follow Us
Phio Pharmaceuticals (PHIO)
NASDAQ:PHIO
PHIO Stock Chart & Stats
$1.19
-$0.09(-4.97%)
At close: 4:00 PM EST
$1.19
-$0.09(-4.97%)
Day’s Range― - ―
52-Week Range$0.81 - $4.19
Previous CloseN/A
Volume62.29K
Average Volume (3M)137.46K
Market Cap
$9.90M
Enterprise Value-$800.65K
Total Cash (Recent Filing)$10.71M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.03
Next Earnings
Mar 25, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding10,764,428
10 Day Avg. Volume82,534
30 Day Avg. Volume137,459
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.30
Price to Sales (P/S)0.00
P/FCF Ratio-0.20
Enterprise Value/Market Cap-0.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.74
Enterprise Value/Ebitda0.10
Forecast
1Y Price Target
$14.00Price Target Upside1076.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 1b results indicate meaningful anti-tumor activity for PH-762, with several patients showing pathologic responses including complete tumor clearances in skin cancers, supporting potential clinical benefit.
Financial RunwayPro forma cash on hand supports continued execution of clinical programs and further investigation of the INTASYL platform, helping to fund ongoing development without immediate financing pressure.
Safety ProfileTrial data show PH-762 was well tolerated across dose cohorts with no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects, which improves the program's safety outlook.
Bears Say
Data Maturity And DurabilityAnalysts view the findings as preliminary due to the early stage of clinical development, and additional data are needed to confirm the durability of observed responses.
Regulatory And Development RiskEarly-stage evidence leaves uncertainty about whether efficacy and safety will be sufficient to support design of larger confirmatory trials and eventual regulatory approval.
Sample Size And GeneralizabilitySmall patient cohorts in the Phase 1b trial limit confidence in how broadly the results will apply across larger or more diverse patient populations.
Phio Pharmaceuticals News
PHIO FAQ
What was Phio Pharmaceuticals’s price range in the past 12 months?
Phio Pharmaceuticals lowest stock price was $0.81 and its highest was $4.19 in the past 12 months.
What is Phio Pharmaceuticals’s market cap?
Phio Pharmaceuticals’s market cap is $9.90M.
When is Phio Pharmaceuticals’s upcoming earnings report date?
Phio Pharmaceuticals’s upcoming earnings report date is Mar 25, 2026 which is in 44 days.
How were Phio Pharmaceuticals’s earnings last quarter?
Phio Pharmaceuticals released its earnings results on Nov 13, 2025. The company reported -$0.44 earnings per share for the quarter, beating the consensus estimate of -$0.45 by $0.01.
Is Phio Pharmaceuticals overvalued?
According to Wall Street analysts Phio Pharmaceuticals’s price is currently Undervalued.
Does Phio Pharmaceuticals pay dividends?
Phio Pharmaceuticals does not currently pay dividends.
What is Phio Pharmaceuticals’s EPS estimate?
Phio Pharmaceuticals’s EPS estimate is -0.34.
How many shares outstanding does Phio Pharmaceuticals have?
Phio Pharmaceuticals has 10,764,428 shares outstanding.
What happened to Phio Pharmaceuticals’s price movement after its last earnings report?
Phio Pharmaceuticals reported an EPS of -$0.44 in its last earnings report, beating expectations of -$0.45. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Phio Pharmaceuticals?
Currently, no hedge funds are holding shares in PHIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Phio Pharmaceuticals
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
PHIO Stock 12 Month Forecast
Average Price Target
$14.00
▲(1076.47% Upside)
Technical Analysis
Ibio
―
Evogene
―
Windtree Therapeutics
―
BioRestorative Therapies
―
Lixte Biotechnology Holdings
―
Ownership Overview
4.21% Insiders
1.36% Mutual Funds
<0.01% Other Institutional Investors
93.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---